42 results about "Tectorigenin" patented technology

The invention relates to application of tectorigenin and derivatives thereof in medicines for preventing and treating insulin resistance diseases, and belongs to the field of biomedicine. The tectorigenin and the derivatives thereof have the effects of preventing and treating the insulin resistance diseases, can promote the glucose uptake capability of insulin target tissues, and enhance the sensitivity of insulin resistance cells to insulin; for insulin resistance mice induced by high-fat diet, the tectorigenin and the derivatives thereof can improve the insulin resistance state of the mice and the resulting hyperglycaemia and hyperinsulinemia, and has definite preventive and therapeutic effects on insulin resistance.

The invention relates to a method of preparing tectorigenin from flowers of kudzuvine. The method comprises the following steps: (1) carrying out aqueous extraction pre-treatment on flower powder of kudzuvine to obtain pre-treated flower powder of kudzuvine; and (2) carrying out ultrasonic flower powder of kudzuvine on the pre-treated flower powder of kudzuvine and then carrying out filtration bymeans of a filter membrane and freeze drying to obtain tectorigenin powder, wherein the content of tectorigenin in the tectorigenin powder is greater than 90%, and the yield is 2.17-2.7%. The purity of tectorigenin prepared from the flowers of kudzuvine is greater than 90% and the yield is about 2.7%. The high purity tectorigenin prepared by the method can serve as a food additive for producing health-care products for preventing tumors, diabetes and the like. Besides ethanol, no other organic reagents are used in an operating method, so that the method is an environment-friendly process method. The operating method provided by the invention is simple and relatively low in demand on equipment, expensive production facilities need not to be invested, the production cost is low, and the method is suitable for industrial batch production.

The invention provides a composition, which has excellent effect of improving tissue differentiation or improving body fat decomposition, improving skin texture, and improving liver function. The composition preferably includes tectorigenin and tectorigenin glucoside with mass ratio of higher than 1:10; and preferably, the tectorigenin glucoside includes a glucoside formed by bonding one saccharide onto tectorigenin and a glucoside formed by bonding two saccharides onto tectorigenin, wherein the mass ratio of the former to the latter is more than 1:0.01 and lower than 1:7.5; more preferably, the glucoside formed by bonding one saccharide onto tectorigenin is tectoridin, and the glucoside formed by bonding two saccharides onto tectorigenin is tectorigenin-7-O-xylose glucoside.

The invention relates to the field of natural medicinal chemistry, in particular to tectorigenin derivatives (I). R is defined as the specification. The derivatives and pharmaceutically acceptable salts thereof have good water solubility and can be used for improving or treating the diseases such as prostatic hypertrophy and/or chronic prostatitis and the like.

The invention discloses a method for separating tectoridin and tectorigenin from water extraction residues of rhizoma iridis tectori, which comprises the following steps of: loading a hydroxypropyl sephadex chromatographic column with a water extraction residue extract of rhizoma iridis tectori, eluting the hydroxypropyl sephadex chromatographic column, and collecting eluent to respectively obtain a tectoridin crude product and an tectorigenin crude product; wherein the diameter-height ratio of the hydroxypropyl sephadex chromatographic column is less than or equal to 1: 25. According to the invention, the tectoridin and the tectorigenin can be simultaneously separated from the water extraction residues of the rhizoma iridis tectori.

The invention belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to a detection method of a traditional Chinese medicine composition for treating chronic pharyngitis. The detection method of the traditional Chinese medicine composition for treating the chronic pharyngitis comprises a step of determining contents of tectoridin, luteolin, cinnamic acid and tectorigenin by a HPLC method. According to the detection method of the traditional Chinese medicine composition for treating the chronic pharyngitis disclosed by the invention, a quality standard of a new preparation can be effectively and strictly formulated; according to a relationship of assistance and guidance, contents of effective ingredients of the traditional Chinese medicine in the preparation are determined, and an experimental research on stability in vitro on the preparation is carried out, so that a good foundation is laid for researching and developing new medicines.

The present invention relates to the use of extracts from Cimicifuga racemosa, and of tectorigenin as an estrogen-type, organoselective medicament for the selective treatment and/or prophylaxis of cardiovascular diseases, atherosclerosis, osteoporosis and climacteric disorders, e.g. for preventing or alleviating hot flushes. Uterotrophic effects are practically not observed.

The invention relates to the technical field of natural pharmaceutical chemistry and medicine, in particular to application of isoflavonoids, namely tectorigenin and tectoridin, in belamcanda chinensis for treating multiple sclerosis diseases. The scheme adopted by the invention is as follows: a model experiment is conducted that 2% of cuprizone is used to induce demyelination of a mouse, and the experimental result shows that tectorigenin and tectoridin can significantly improve the pathological alteration and ultrastructural changes of demyelination at the callosum part of the mouse in the cuprizone-induced demyelination model; both of tectorigenin and tectoridin can significantly reverse the performance of a decreased myelin-associated protein expression level of the demyelinated mouse induced by cuprizone; both of tectorigenin and tectoridin can significantly alleviate the depression-like behaviors and the spatial learning and memory impairments of the mouse in the demyelination model, and show a remarkable protective function. Therefore, the two isoflavonoids namely tectorigenin and tectoridin can be used to prepare medicine for treating multiple sclerosis related diseases.

The invention discloses a tectorigenin sun protection skin care product. The tectorigenin sun protection skin care product contains, by weight, 0.05%-0.3% of tectorigenin. The tectorigenin sun protection skin care product adopts natural herbaceous plants, is more stable in property, has no stimulus to the skin, can supply most effective protection to the skin to the maximum limit and can be directly applied to the portions, prone to exposure, of the face, the neck and the hands. According to the tectorigenin sun protection skin care product, a pure natural sun protection skin care composition is natural in skin feel and not greasy, a sample passes through the safety and stability testing standard, the application value of actual cosmetic production is achieved, and through SPF 290S testing, the sun protection factor (SPF) reaches 15-30. The tectorigenin sun protection skin care product has the good sun protection, ultraviolet protection and moisturizing effects.

The invention discloses a method for preparing a flavonoid compound by separating flos puerariae, and belongs to the field of preparation methods of plant natural products. The flavonoid compound is 3'-hydroxyl tectorigenin-7-O-beta-D-xylosyl-(1->6)-beta-D-glucopyranoside. According to the preparation method disclosed by the invention, zirconium oxide is used as a separation medium, and the flavonoid compound is obtained by separation through the steps of synthesizing the zirconium oxide, preparing flos puerariae crude extract, performing zirconium oxide adsorption, performing washing with distilled water and performing acetic acid desorption. The purity of the flavonoid compound reaches 90% or above, and the yield of the flavonoid compound is about 0.6%. According to the preparation method disclosed by the invention, other organic solvents are not used except acetic acid and ethyl acetate, so that the preparation method is an environment-friendly separation method; and the separationpreparation method is simple in process, free of expensive production facilities, low in product cost and suitable for industrial production.

The invention discloses clostridium AUH-JLC39 with a preservation number of CGMCC No. 7221 and application of the clostridium AUH-JLC39 in conversion of tectorigenin. The application of the clostridium AUH-JLC39 in the conversion of the tectorigenin comprises the steps of grafting seed solution of bacterial strain JLC39 to a liquid medium according to 10-15% inoculation amount, adding substrate tectorigenin, standing and cultivating for 48-60 hours in an anaerobic working station, extracting culture twice using ethyl acetate with a same volume, evaporating the extracting liquid and separating and manufacturing the product on HPLC using a preparatory column. The bacterial strain can effectively convert the tectorigenin to dihydro tectorigenin, and the external clearing rate of the dihydro tectorigenin to DPPH is very remarkable and is higher than the substrate tectorigenin (p (0.01). The clostridium AUH-JLC39 solves the problem of microorganism synthesis of the dihydro tectorigenin and lack of resources, and has significant pushing effect of new medicine development.

The invention discloses application of CDK in preparation and screening of anti-hepatoma drugs, and application of New Tectorigenin as a CDK inhibitor in regulating HepG2 cell cycle. The inventor of the application finds that New Tectorigenin can inhibit proliferation of HepG2 cells by inhibiting synthesis of CDK2, CDK4 and CDK6 proteins in the HepG2 cell cycle, and therefore, as a CDK inhibitor,New Tectorigenin can inhibit proliferation of HepG2, having an important meaning for developing a new generation of anti-hepatoma drugs.

The invention discloses a method for directly extracting tectorigenin from lobed kudzuvine flowers. The method includes the steps: first, crushing the lobed kudzuvine flowers, sieving the lobed kudzuvine flowers by a 60-mesh sieve, weighing lobed kudzuvine flower powder, adding the powder into hydrochloric acid solution with the concentration of 0.1-2.0mol/L, placing the solution into a thermostatic water bath, performing hydrolysis for 2-6 hours, setting hydrolysis temperature to range from 50 DEG C to 90 DEG C and centrifuging the solution after hydrolysis to obtain lower precipitates; second, washing the precipitates with distilled water to be neutral, adding 200mL of 85% ethanol solution, performing extraction for 2 hours at the temperature of 60 DEG C and centrifugally abandoning thelower precipitates to obtain supernatant extracting solution; performing cryoprecipitation on the supernatant extracting solution at the temperature of 4 DEG C for 4 hours and performing centrifugation to obtain supernate; third, performing vacuum concentration on the obtained supernate to 10-20mL, adding obtained concentrated solution into 10 times of 70 DEG C distilled water, stirring and blending the concentrated solution and the distilled water, cooling mixture to room temperature, performing cryoprecipitation at the temperature of 4 DEG C for 12 hours, performing centrifugation to take precipitates, and freeze-drying the precipitates for 36 hours to obtain extracted powder, namely, the tectorigenin. The tectorigenin is directly extracted from the lobed kudzuvine flowers without tectoridin extraction steps, technologies are simple, and tectorigenin extraction rate is high.

The present invention relates to the use of extracts from Iridaceae and from Cimicifuga racemosa, and of tectorigenin as an estrogen-type, organoselective medicament for the selective treatment and/or prophylaxis of cardiovascular diseases, in particular atherosclerose, osteoporose and climacteric disorders, e.g. for preventing or alleviating hot flushes. Uterotrophic effects are practically not observed.